Pulse Biosciences, Inc. (PLSE) — 8-K Filings

8-K Filings (40)

• 8-K Filing — May 6, 2026
• Pulse Biosciences Files 8-K with Exhibits — Apr 16, 2026 Risk: low
  On April 16, 2026, Pulse Biosciences, Inc. filed an 8-K report detailing its financial statements and exhibits. The filing includes various graphic files, likel
• 8-K Filing — Apr 9, 2026
• 8-K Filing — Apr 7, 2026
• 8-K Filing — Dec 18, 2025
• 8-K Filing — Dec 12, 2025
• 8-K Filing — Dec 9, 2025
• 8-K Filing — Nov 13, 2025
• Pulse Biosciences Files 8-K — Oct 24, 2025 Risk: low
  On October 24, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Pulse Biosciences Files 8-K — Oct 10, 2025 Risk: low
  Pulse Biosciences, Inc. filed an 8-K on October 10, 2025, reporting other events and financial statements. The company, formerly known as Electroblate, Inc., is
• Pulse Biosciences Files 8-K on Shareholder Votes & Other Events — Oct 1, 2025 Risk: low
  Pulse Biosciences, Inc. filed an 8-K on October 1, 2025, reporting on events that occurred on September 30, 2025. The filing indicates a submission of matters t
• Pulse Biosciences Files 8-K Report — Sep 8, 2025 Risk: low
  On September 8, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no
• Pulse Biosciences Files 8-K — Sep 2, 2025 Risk: low
  On September 2, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no
• Pulse Biosciences Files 8-K — Aug 26, 2025 Risk: low
  Pulse Biosciences, Inc. filed an 8-K on August 26, 2025, reporting other events and financial statements. The company, formerly known as Electroblate, Inc., is
• Pulse Biosciences Appoints New CEO, Dr. Darrin Uecker — Jul 14, 2025 Risk: medium
  Pulse Biosciences, Inc. announced on July 14, 2025, the appointment of Dr. Darrin Uecker as Chief Executive Officer, effective immediately. Dr. Uecker, who prev
• Pulse Biosciences Files 8-K on Financials — Mar 28, 2025 Risk: low
  Pulse Biosciences, Inc. filed an 8-K on March 28, 2025, reporting on its results of operations and financial condition as of March 27, 2025. The filing includes
• Pulse Biosciences Files 8-K: Officer/Director Changes & Financials — Feb 4, 2025 Risk: medium
  Pulse Biosciences, Inc. filed an 8-K on February 4, 2025, reporting on events as of January 31, 2025. The filing includes information regarding the departure of
• Pulse Biosciences Files 8-K for Financials and Exhibits — Jan 23, 2025 Risk: low
  On January 21, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material eve
• Pulse Biosciences Files 8-K Report — Jan 14, 2025 Risk: low
  On January 14, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD disclosur
• Pulse Biosciences Announces Director, Officer Changes — Jan 13, 2025 Risk: medium
  Pulse Biosciences, Inc. announced on January 9, 2025, a series of significant corporate actions. These include the election of new directors, the appointment of
• Pulse Biosciences Files 8-K — Dec 26, 2024 Risk: low
  On December 23, 2024, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
• Pulse Biosciences Announces Executive and Board Changes — Dec 6, 2024 Risk: medium
  Pulse Biosciences, Inc. announced on December 2, 2024, a series of executive and board changes. Effective December 2, 2024, Darrin R. Uecker resigned as Preside
• Pulse Biosciences Relocates Executive Offices to Miami — Nov 26, 2024 Risk: low
  On November 26, 2024, Pulse Biosciences, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices from Hayward, Cali
• Pulse Biosciences Files 8-K — Oct 31, 2024 Risk: low
  Pulse Biosciences, Inc. filed an 8-K on October 31, 2024, reporting other events and financial statements. The company, incorporated in Delaware, is involved in
• Pulse Biosciences Acquires Lumina Health for $10M — Aug 12, 2024 Risk: medium
  Pulse Biosciences, Inc. announced on August 9, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Lumina Healt
• Pulse Biosciences Appoints New CFO, Grants Stock Options — Aug 8, 2024 Risk: medium
  On August 8, 2024, Pulse Biosciences, Inc. filed an 8-K report detailing the appointment of Kevin L. Johnson as Chief Financial Officer, effective August 5, 202
• Pulse Biosciences Files 8-K on Material Agreement — Jul 15, 2024 Risk: medium
  On July 15, 2024, Pulse Biosciences, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers results of operations and financ
• Pulse Biosciences Merges with Lumena Pharmaceuticals — Jul 8, 2024 Risk: medium
  On July 8, 2024, Pulse Biosciences, Inc. filed an 8-K report detailing the closing of its previously announced business combination with privately held company,
• Pulse Biosciences Files 8-K — Jul 3, 2024 Risk: low
  Pulse Biosciences, Inc. filed an 8-K on July 3, 2024, to report other events and financial statements. The company, formerly known as Electroblate, Inc., is inc
• Pulse Biosciences Files 8-K — Jun 28, 2024 Risk: low
  Pulse Biosciences, Inc. filed an 8-K on June 28, 2024, to report other events and financial statements. The filing does not contain specific financial figures o
• Pulse Biosciences Appoints New CFO, Elects Directors — Jun 7, 2024 Risk: medium
  Pulse Biosciences, Inc. announced on June 6, 2024, the appointment of Kevin J. O'Malley as its new Chief Financial Officer, effective immediately. O'Malley, who
• Pulse Biosciences Files 8-K — Jun 4, 2024 Risk: low
  Pulse Biosciences, Inc. filed an 8-K on June 4, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
• Pulse Biosciences Files 8-K Report — May 20, 2024 Risk: low
  On May 20, 2024, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific
• Pulse Biosciences Appoints New CFO — May 15, 2024 Risk: medium
  Pulse Biosciences, Inc. announced on May 12, 2024, the appointment of Kevin J. O'Malley as its new Chief Financial Officer, effective May 13, 2024. O'Malley wil
• Pulse Biosciences Closes $20M Public Offering — May 9, 2024 Risk: medium
  On May 9, 2024, Pulse Biosciences, Inc. filed an 8-K report detailing the closing of a previously announced underwritten public offering. The company successful
• Pulse Biosciences Files 8-K Report — May 2, 2024 Risk: low
  On May 2, 2024, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, with no other specif
• Pulse Biosciences Sells ElectroBlate Subsidiary — Mar 11, 2024 Risk: medium
  Pulse Biosciences, Inc. announced on March 8, 2024, that it has entered into a definitive agreement to sell its ElectroBlate, Inc. subsidiary to an undisclosed
• Pulse Biosciences Files Standard 8-K on Feb 14 — Feb 14, 2024 Risk: low
  Pulse Biosciences, Inc. filed a Form 8-K with the SEC on February 14, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing confirm
• Pulse Biosciences Files 8-K for Regulation FD Disclosure — Jan 9, 2024
  Pulse Biosciences, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and to file financial statements and exhibits. This filing,
• Pulse Biosciences Files Routine 8-K on Jan 2, 2024 — Jan 2, 2024
  Pulse Biosciences, Inc. filed an 8-K on January 2, 2024, to report an "Other Event" and provide financial statements and exhibits. This filing, under the Securi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX